Werewolf Therapeutics GAAP EPS of -$0.20 beats by $0.14

What: Werewolf Therapeutics reported a GAAP EPS of -$0.20, beating the estimated loss by $0.14.
Why: The company's earnings beat is attributed to its successful cost-cutting measures and efficient use of resources.
Signal: This earnings beat signals a potential turnaround in the company's financial performance.
Target: The target price for Werewolf Therapeutics stock may be revised upwards following this earnings beat.
Risk: However, the company still faces significant risks related to its pipeline of experimental treatments.